Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II/III: Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Trial of BHV-3500 for the Acute Treatment of Migraine

Next Previous
Search
Trial Profile

Phase II/III: Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Trial of BHV-3500 for the Acute Treatment of Migraine

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 27 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zavegepant (Primary)
  • Indications Migraine; Migraine with aura; Migraine without aura
  • Focus Registrational; Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 27 Apr 2023 Pooled data (N=2061) from NCT03872453, NCT04571060 presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 27 Apr 2023 Results of post-hoc subgroup pooled analysis (N=2061; zavegepant n=1014, placebo n=1047) from NCT03872453 and NCT04571060 assessing the influence of attack frequency on the efficacy of zavegepant nasal spray in the acute treatment of migraine, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 10 Mar 2023 According to a Pfizer Inc. media release, based on two pivotal randomized, double-blind, placebo-controlled studies, U.S. Food and Drug Administration (FDA) has approved ZAVZPRET(zavegepant), nasal spray for the acute treatment of migraine with or without aura in adults.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top